Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis

Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Key Stats

• Today's Range: $38.00 to $39.46
• 50-Day Range: $38.31 to $45.74
• 52-Week Range: $35.53 to $50.99
• Volume: 1.05 million shs
• Average Volume: 391,447 shs
• Market Capitalization: $2.95 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Buy

Xenon Pharmaceuticals Stock Analysis - MarketRank™

Xenon Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 488th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Xenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Xenon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($3.10) to ($3.74) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Xenon Pharmaceuticals is -13.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Xenon Pharmaceuticals is -13.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Xenon Pharmaceuticals has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.78% of the outstanding shares of Xenon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Xenon Pharmaceuticals has recently decreased by 2.04%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Xenon Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Xenon Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.78% of the outstanding shares of Xenon Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Xenon Pharmaceuticals has a short interest ratio ("days to cover") of 7.8.

Change versus previous month

Short interest in Xenon Pharmaceuticals has recently decreased by 2.04%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.80

News Sentiment

Xenon Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Xenon Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for XENE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

3 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $971,920.00 in company stock.

Percentage Held by Insiders

Only 5.52% of the stock of Xenon Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XENE Stock Analysis - Frequently Asked Questions

How have XENE shares performed this year?

Xenon Pharmaceuticals' stock was trading at $46.06 at the beginning of 2024. Since then, XENE shares have decreased by 16.1% and is now trading at $38.63.
View the best growth stocks for 2024 here.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01.

Who are Xenon Pharmaceuticals' major shareholders?

Top institutional investors of Xenon Pharmaceuticals include FMR LLC (9.13%), Wellington Management Group LLP (5.04%), Braidwell LP (3.57%) and Janus Henderson Group PLC (3.35%). Insiders that own company stock include Dawn Svoronos, Ian Mortimer, Gary Patou, James R Empfield, Sherrington Robin, Simon N Pimstone, Steven Gannon, Sherry Aulin and Christopher John Kenney.
View institutional ownership trends.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Xenon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Deckers Outdoor (DECK), Adobe (ADBE) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XENE
• CUSIP: N/A
• CIK: 1582313
• Web: www.xenon-pharma.com
• Phone: (604) 484-3300
• Fax: 604-484-3450
• Employees: 251
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $56.00
• High Stock Price Target: $65.00
• Low Stock Price Target: $49.00
• Potential Upside/Downside: +45.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.11
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-182,390,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -24.69%
• Return on Assets: -23.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.21
• Quick Ratio: 22.21

Sales & Book Value

• Annual Sales: $9.43 million
• Price / Sales: 312.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.18 per share
• Price / Book: 2.72

Miscellaneous

• Outstanding Shares: 76,240,000
• Free Float: 72,032,000
• Market Cap: $2.95 billion
• Optionable: Optionable
• Beta: 1.19